Everything you need to know about minoxidil tablets

DoktorABC editorial team

Accurate, up-to-date health information written by our editorial team and reviewed by UK-registered prescribers.

What are minoxidil tablets?

Minoxidil tablets are the oral form of minoxidil, taken once daily rather than applied to the scalp. In the UK, minoxidil tablets are licensed as an antihypertensive medicine (for treating high blood pressure), not for hair loss. Their use for androgenetic alopecia is therefore off-label, meaning it is outside the terms of the medicine's UK marketing authorisation.

Off-label prescribing is legal and common in UK clinical practice, and low-dose oral minoxidil (LDOM) for hair loss has a growing and credible evidence base. A 2025 international expert consensus statement published in JAMA Dermatology, involving dermatologists from multiple countries, concluded that the off-label use of low-dose oral minoxidil may be safe and effective for patients with hair loss, and provided clinical guidance to support prescribing practice until larger trials and standardised guidelines are available. 

How oral minoxidil tablets work

The mechanism of oral minoxidil is the same as topical minoxidil, but the delivery route is different. When taken orally, minoxidil is absorbed through the digestive system and circulates systemically in the bloodstream. It is then converted into its active metabolite, minoxidil sulfate, by enzymes in the body.

Minoxidil sulfate opens ATP-sensitive potassium channels in smooth muscle cells, causing vasodilation. In the context of hair loss, this increases blood flow to hair follicles across the scalp, prolonging the active growth phase (anagen) and partially reversing the miniaturisation of follicles associated with androgenetic alopecia.

Because the tablet acts systemically rather than locally, it reaches follicles across the entire scalp through the bloodstream rather than by direct application. This is one reason why some patients see more uniform coverage improvement with oral minoxidil than with topical, and why the crown advantage observed in some trials may reflect more consistent drug delivery to that region.

Clinical evidence for minoxidil tablets

The evidence base for low-dose oral minoxidil has grown substantially over the past five years.

In 2025, low-dose oral minoxidil emerged as a widely used off-label treatment for different types of alopecia, with a favourable safety profile and meaningful effectiveness.

A retrospective analysis of 41 men with male pattern hair loss treated with oral minoxidil 2.5 mg or 5 mg demonstrated clinical improvement in 90% of cases. 

A randomised clinical trial comparing oral minoxidil 5 mg per day with twice-daily topical minoxidil 5% found no statistically significant difference in terminal hair density between the two groups on the frontal scalp, while oral minoxidil showed a numerically greater improvement in the vertex (crown) area. 

The overall picture from the available evidence is that oral minoxidil at low doses is broadly comparable in efficacy to topical minoxidil 5%, with some potential advantages in the crown region and meaningful practical advantages in terms of adherence and tolerability.

Minoxidil tablets for men

In clinical practice, doses used for male androgenetic alopecia typically range from 1.25 mg to 5 mg once daily. Current expert consensus recommends using low-dose oral minoxidil at the lowest effective dose, not exceeding 5 mg per day for hair loss, to minimise the risk of adverse events while maintaining efficacy. 

Most prescribers start men at a lower dose, typically 1.25 mg or 2.5 mg, and titrate upward based on response and tolerability. The dose is always determined by your prescriber based on your individual health profile and response to treatment.

Minoxidil tablets for women

Women tend to be prescribed lower doses than men. In a retrospective review of women with female pattern hair loss treated with low-dose oral minoxidil, the most common starting dose was 1.25 mg daily (52% of patients), followed by 2.5 mg daily (40%), and 0.625 mg daily (8%). Notably, 40% of patients in this study had previously tried topical minoxidil and discontinued it due to local side effects or adherence difficulty, highlighting oral minoxidil as a practical alternative. 

For women, the lower dose range is preferred because hypertrichosis (unwanted body hair growth) is reported at higher rates in women and increases with dose. This is the most commonly reported reason for treatment review in female patients, though most women find it manageable.

Minoxidil and finasteride tablets: Can they be taken together?

Yes, and the combination is increasingly used in clinical practice. Finasteride addresses the hormonal driver of androgenetic alopecia by reducing DHT levels; oral minoxidil stimulates follicular activity through an entirely different mechanism. The two approaches are complementary.

A 2025 meta-analysis of seven randomised controlled trials demonstrated superior efficacy of the topical minoxidil and finasteride combination over minoxidil monotherapy, with clinically meaningful improvements in hair density, hair diameter, and global photographic assessment. 

While this evidence relates to topical rather than oral combination, the principle of complementary mechanisms applies equally to oral minoxidil. For a full discussion, see our guide on finasteride and minoxidil together.

Minoxidil and cardiovascular safety

At the low doses used for hair loss (typically 0.625 mg to 5 mg daily), the cardiovascular effect is considerably smaller than at the antihypertensive doses of 10 to 40 mg daily.

A study of 30 adult males taking 5 mg oral minoxidil for androgenetic alopecia, assessed with 24-hour blood pressure monitoring before and after 24 weeks of treatment, found a statistically significant but clinically irrelevant reduction in mean arterial pressure, and none of the patients experienced clinical hypotension. A modest increase in heart rate of 5.6 beats per minute was detected.

Cardiovascular adverse effects including postural hypotension, tachycardia, and lower limb oedema are relatively common at antihypertensive minoxidil doses of 10 to 100 mg per day, but are minor and rare at low doses used for hair loss. 

The most important practical implication is that patients with pre-existing cardiovascular conditions, significant hypotension, or those taking multiple antihypertensive medicines require careful assessment before starting oral minoxidil. For most otherwise healthy adults, the cardiovascular risk at low doses is considered acceptable under prescriber supervision.

Side effects specific to oral tablets

The side effect profile of oral minoxidil differs from topical in several important ways. Because the medicine circulates systemically, side effects can affect areas beyond the scalp.

The most frequent adverse event with low-dose oral minoxidil is hypertrichosis, occurring in approximately 15% of patients, with a higher incidence in women and at higher doses. Fluid retention affects 1.3 to 10% of patients, particularly women, and typically occurs within one to three months of treatment. 

Key side effects to be aware of:

• Hypertrichosis: Unwanted hair growth on the face, arms, or other body areas. More common in women and at higher doses. Most patients find it manageable; it is the leading reason for dose reduction or discontinuation.
• Fluid retention: Mild ankle swelling is the most common presentation. More frequent in women and those predisposed to fluid retention.
• Modest heart rate increase: A small increase in resting heart rate has been observed in studies at 5 mg doses, though this was not clinically significant in available data.
• Scalp irritation: Unlike with topical minoxidil, this is not an issue with the tablet form, which is one reason some patients switch from topical to oral.

Who should not take oral minoxidil

Oral minoxidil is contraindicated and requires careful prescriber assessment in patients who:

• Are pregnant, planning pregnancy, or breastfeeding
• Have significant cardiovascular disease, including heart failure or a history of pericardial effusion
• Have significantly low blood pressure (hypotension)
• Have phaeochromocytoma (a rare adrenal gland tumour)
• Have significant kidney or liver impairment
• Are taking multiple antihypertensive medicines, where an additive blood pressure effect requires monitoring

How to access minoxidil tablets in the UK

Oral minoxidil is prescription-only in the UK. There are two main routes to access.

Via your GP: Some GPs prescribe oral minoxidil off-label for hair loss, though availability varies between practices and NHS funding is unlikely for this indication.

Via a regulated online clinic: Private online clinics connect you with UK-registered prescribers who can assess your suitability and issue a private prescription. 

Final thoughts

Low-dose oral minoxidil is a well-evidenced and increasingly widely used option for hair loss that offers genuine practical advantages over topical application for many patients. The evidence base continues to grow, and the 2025 international expert consensus statement provides prescribers with a clear framework for its use.

As with any prescription medicine, the starting point is a thorough medical assessment. Oral minoxidil is not appropriate for everyone, and the cardiovascular and systemic considerations require individual clinical review.

FAQ

The DoktorABC medical advisory board

Dr. Roland Ruiken

Medical advisor, Norway

Dr. Viktor Simunovic

Medical advisor, Croatia

To the medical advisory board